[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"portal-shunt-systemic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:portal-shunt-systemic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100635528","endoscopic-shunts-embolization-for-refractory-hepatic-encephalopathy-100635528",false,"NCT07553858","Endoscopic Shunts Embolization for Refractory Hepatic Encephalopathy","Endoscopic Ultrasound Embolization of Porto-Systemic Shunt for Management of Medically Refractory Hepatic Encephalopathy: A Randomized Trial","Inclusion Criteria:\n\n1. Adults aged ≥18 years with known cirrhosis\n2. MRHE; defined as ≥2 episodes of hepatic encephalopathy, HE (as documented in an outpatient office visit or during an inpatient admission) within 6 months prior to enrollment despite medical therapy with lactulose and rifaximin\n3. Admission to inpatient hepatology floor at University Hospital-Newark with MRHE at the time of enrollment\n4. Presence of a spontaneous portosystemic shunt; confirmed on CT\u002FMRI at the index admission.\n\nExclusion Criteria:\n\n1. Severe\u002Frefractory ascites defined as ascites that does not recede after medical therapy or reoccurs shortly after fluid has been removed\n2. Refractory or recurrent bleeding from esophageal varices\n3. Presence of portal vein thrombosis with complete occlusion\n4. Hepatocellular carcinoma beyond Milan criteria or other advanced malignancy with limited life expectancy (\\\u003C6 months)\n5. Platelet count of less than 35,000 and\u002For INR of more than 2 which cannot be corrected for the EUS guided embolization procedure.\n6. Hepatic venous occlusion, or right heart failure as the etiology of cirrhosis.","ALL","18 Years",{"count":19,"type":20},34,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if endoscopic ultrasound guided (EUS guided) spontaneous porto-systemic shunt (SPSS) embolization works to treat refractory hepatic encephalopathy in adults. It will also learn about the safety of EUS guided embolization. The main questions it aims to answer are:\n\n1. Does EUS guided embolization maintain an acceptable safety profile?\n2. Does EUS guided embolization of large SPSS result in significant clinical improvement in patients with refractory hepatic encephalopathy?\n\nParticipants will:\n\n1. Receive EUS guided embolization or medical management.\n2. Receive follow-up EUS procedures one month after embolization for assessment of the shunt patency and development of varices (embolization group).\n3. Receive follow-up every week for 4 weeks to assess degree of worst episode of hepatic encephalopathy via West Haven criteria.",[26,27,28],"Hepatic Encephalopathy","Liver Cirrhosis","Portal Shunt Systemic","NOT_YET_RECRUITING","2026-04-20",{"date":32,"type":33},"2026-04-28","ACTUAL",{"date":35,"type":20},"2026-05-01",{"date":37,"type":20},"2028-11-01",{"name":39,"class":40},"Rutgers, The State University of New Jersey","OTHER"]